非小细胞肺癌组织中肝再生磷酸酶-2和-3表达及微血管密度相关性分析

Expressions of phosphatase of regenerating liver-2 and-3 and their correlation with microvessel density in non-small cell lung cancer tissues

目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中肝再生磷酸酶(phosphatase of regenerating liver,PRL)-2、PRL-3表达情况及与微血管密度(microvessel density,MVD)的相关性,分析其表达与临床病理指标间的相关性。方法采用免疫组织化学法检测40例NSCLC患者癌组织及癌旁正常组织中PRL-2、PRL-3表达情况,并检测癌组织中MVD值,分析PRL-2、PRL-3表达水平与MVD值间相关性及其与临床病理参数间关系。结果 PRL-2、PRL-3在癌组织中阳性表达率分别为65%、70%,其表达在肿瘤分化程度、淋巴结转移情况及TNM分期上差异有统计学意义(P<0.05),在癌旁组织中均未发现阳性表达;NSCLC患者癌组织MVD值在年龄、肿瘤淋巴结转移情况及TNM分期上差异有统计学意义(P<0.05);PRL-2与PRL-3(r=0.452,P=0.008)、PRL-2与MVD(r=0.536,P=0.000)、PRL-3与MVD(r=0.452,P=0.004)呈明显正相关;PRL-2、PRL-3阳性表达者及MVD值>40者出现疾病进展例数明显高于PRL-2、PRL-3阴性者及MVD值≤40者(P<0.05)。结论 PRL-2、PRL-3异常表达时可能通过影响肿瘤新生血管的形成而促进肺癌的形成、增殖及侵袭,对临床诊疗及判定预后有一定价值。

Objective To investigate the expressions of phosphatase of regenerating liver-2 （PRL 2） and phosphatase of regenerating live-3 （PRL-3） in non-small cell lung cancer （NSCLC） tissues, and the correlation with microvessel density （MVD）, to analyze the relationship of the expressions with clinical and pathological parameters. Methods The expressions of PRL 2 and PRL-3 were detected in 40 cases of NSCLC tissues and normal adjacent tissues by using immunohistochemistry method, and MVD values were detected in NSCLC tissues. The correlation of the expressions of PRL-2 and PRL-3 with MVD and different clinical and pathological parameters were analyzed. Results The positive expression rates of PRL-2 and PRL-3 were 65 % and 70% in tumor tissues, showing significant differences in the degrees of differentiation, lymph node metastasis status and TNM stages of tumors （P〈0.05）. The positive expression was not found in normal tissues. There were significant differences in MVD values in lymph node metastasis status and TNM stages in NSCLC tissues （P〈0.05）. There were positive correlations between PRL-2 and PRL-3 （r=0. 452, P= 0.008）, PRL-2 and MVD （r=0.536, P=0.000）, and between PRL-3 and MVD （r=0.452, P=0.004）. There were more cases of progressive disease in patients with positive expressions of PRL-2 and PRL-3 and MVD value over 40 than in those with negative expressions of PRL 2 and PRL-3 and MVD value of 40 or lower （P〈0.05）. Conclusion The abnormal expressions of PRL-2 and PRL-3 provide a feasible theoretical basis for clinical diagnosis, treatment and prognosis by promoting the formation, proliferation and invasion of lung cancer through tumor neovascularity.